Payment overview · 2025
General Payments
$7,772.10
439 reported records · 28 companies
Healthcare provider profile · identity verified
Antoine E Mitri, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · DOWNEY, CA · NPI 1215945530
Verified facts
What the public records show
CMS Open Payments records show Antoine E Mitri, MD received $7,772.10 in general payments during 2025 across 439 reported records.
LivaNova USA, Inc. accounted for 17.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Briviact, Fycompa, Gocovri, Ingrezza, Nayzilam, Nurtec Odt, Valtoco, Vraylar, Xcopri.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Vraylar by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rytary by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TECFIDERA as an associated drug or biological on 28 records involving 22 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Tecfidera by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Fycompa by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gocovri as an associated drug or biological on 3202 records involving 1029 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Gocovri by this doctor in 2024.
Neurelis, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VALTOCO as an associated drug or biological on 16082 records involving 5567 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Valtoco by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xcopri by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Austedo by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Austedo Xr by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Briviact by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nayzilam as an associated drug or biological on 9542 records involving 3826 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nayzilam by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $1,324.54 | 17.0% | 87 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $1,154.63 | 14.9% | 41 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$911.89 | 11.7% | 70 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $528.66 | 6.8% | 19 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $461.46 | 5.9% | 39 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $400.61 | 5.2% | 17 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $366.36 | 4.7% | 17 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $301.02 | 3.9% | 25 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $268.15 | 3.5% | 10 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$262.41 | 3.4% | 19 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $252.78 | 3.2% | 10 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $229.31 | 3.0% | 15 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $221.69 | 2.9% | 11 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $197.82 | 2.5% | 19 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $130.98 | 1.7% | 8 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $119.53 | 1.5% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $117.90 | 1.5% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $104.53 | 1.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $84.07 | 1.1% | 4 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $67.56 | 0.9% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $54.65 | 0.7% | 3 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $54.31 | 0.7% | 2 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $39.83 | 0.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $30.87 | 0.4% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $26.64 | 0.3% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $22.69 | 0.3% | 1 | 2025 |
| Forte Bio-Pharma LLC | Unresolved — no canonical attribution shown | $20.37 | 0.3% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $16.84 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $7,070.61 | 433 |
| Travel and Lodging | $397.98 | 1 |
| Education | $303.51 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VNS Therapy Normalized: vns therapy |
Device | LivaNova USA, Inc. | $898.25 | 10 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $426.29 | 77 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $417.81 | 14 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $400.61 | 17 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $373.97 | 14 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $329.68 | 17 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $325.13 | 30 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $301.02 | 25 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $268.15 | 10 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $262.41 | 19 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $252.78 | 10 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $231.97 | 21 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $221.69 | 11 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $196.07 | 7 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $175.23 | 6 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $173.61 | 13 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $166.78 | 6 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $149.42 | 9 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $130.98 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $129.49 | 8 | 2025 |
Source payment records
|
|||||
| XCOPRI Normalized: xcopri |
Drug | SK Life Science, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $117.90 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $117.90 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $112.24 | 8 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $104.53 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $84.07 | 4 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $67.56 | 3 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $54.31 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $39.83 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $30.87 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $26.64 | 1 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $22.69 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| TANLOR Normalized: tanlor |
Drug | Forte Bio-Pharma LLC | $20.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Briviact briviact |
2025 | Briviact | 2024 | 82 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Gocovri gocovri |
2025 | Gocovri | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Nayzilam nayzilam |
2025 | Nayzilam | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VALTOCO valtoco |
2025 | Valtoco | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XCOPRI xcopri |
2025 | Xcopri | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TECFIDERA open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 22 recipient NPIs · example record 1208304358 |
Tecfidera · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Gocovri open payments reported associated product |
CMS Open Payments — General Payments 3202 supporting records · 1029 recipient NPIs · example record 1241843637 |
Gocovri · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Neurelis, Inc. Exact reporting entity; no affiliate inference |
2025 | VALTOCO open payments reported associated product |
CMS Open Payments — General Payments 16082 supporting records · 5567 recipient NPIs · example record 1219183925 |
Valtoco · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
82 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Nayzilam open payments reported associated product |
CMS Open Payments — General Payments 9542 supporting records · 3826 recipient NPIs · example record 1224348539 |
Nayzilam · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 1321 | 392 |
| Gabapentin | Gabapentin | 1228 | 443 |
| Levetiracetam | Levetiracetam | 1075 | 217 |
| Ropinirole Hcl | Ropinirole Hcl | 696 | 197 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 667 | 160 |
| Memantine Hcl | Memantine Hcl | 521 | 161 |
| Lacosamide | Lacosamide | 477 | 54 |
| Nortriptyline Hcl | Nortriptyline Hcl | 477 | 151 |
| Duloxetine Hcl | Duloxetine Hcl | 407 | 136 |
| Carbamazepine | Carbamazepine | 380 | 71 |
| Topiramate | Topiramate | 348 | 71 |
| Pregabalin | Pregabalin | 299 | 67 |
| Lamotrigine | Lamotrigine | 280 | 46 |
| Phenobarbital | Phenobarbital | 256 | 30 |
| Primidone | Primidone | 233 | 52 |
| Divalproex Sodium Er | Divalproex Sodium | 198 | 38 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 188 | 38 |
| Trazodone Hcl | Trazodone Hcl | 184 | 57 |
| Sertraline Hcl | Sertraline Hcl | 172 | 49 |
| Divalproex Sodium | Divalproex Sodium | 166 | 33 |
| Oxcarbazepine | Oxcarbazepine | 109 | 23 |
| Mirtazapine | Mirtazapine | 108 | 36 |
| Carbamazepine Er | Carbamazepine | 107 | 15 |
| Clonazepam | Clonazepam | 102 | 15 |
| Olanzapine | Olanzapine | 102 | 26 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 102 | 12 |
| Baclofen | Baclofen | 97 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 86 | 20 |
| Zonisamide | Zonisamide | 83 | 19 |
| Briviact | Brivaracetam | 82 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 82 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 79 | 19 |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 79 | 16 |
| Rivastigmine | Rivastigmine | 75 | 23 |
| Memantine Hcl Er | Memantine Hcl | 61 | 17 |
| Meclizine Hcl | Meclizine Hcl | 57 | 32 |
| Entacapone | Entacapone | 55 | 17 |
| Ibuprofen | Ibuprofen | 55 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 49 | 12 |
| Amantadine | Amantadine Hcl | 47 | 13 |
| Clobazam | Clobazam | 47 | suppressed |
| Phenytoin | Phenytoin | 45 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 44 | 17 |
| Aptiom | Eslicarbazepine Acetate | 42 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 42 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 40 | suppressed |
| Lidocaine | Lidocaine | 40 | 19 |
| Risperidone | Risperidone | 40 | 11 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 37 | suppressed |
| Meloxicam | Meloxicam | 35 | 12 |
| Copaxone | Glatiramer Acetate | 33 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 32 | 14 |
| Glatopa | Glatiramer Acetate | 31 | suppressed |
| Tegretol | Carbamazepine | 31 | suppressed |
| Ingrezza | Valbenazine Tosylate | 30 | suppressed |
| Austedo Xr | Deutetrabenazine | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 11 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 26 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 25 | suppressed |
| Hizentra | Immun Glob G(Igg)/Pro/Iga 0-50 | 24 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 24 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 23 | suppressed |
| Fycompa | Perampanel | 23 | suppressed |
| Vimpat | Lacosamide | 23 | suppressed |
| Tecfidera | Dimethyl Fumarate | 22 | suppressed |
| Austedo | Deutetrabenazine | 21 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Neupro | Rotigotine | 18 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 18 | suppressed |
| Vraylar | Cariprazine Hcl | 18 | suppressed |
| Valtoco | Diazepam | 17 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Nayzilam | Midazolam | 16 | suppressed |
| Keppra Xr | Levetiracetam | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Nourianz | Istradefylline | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Dalfampridine Er | Dalfampridine | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Rytary | Carbidopa/Levodopa | 13 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Xcopri | Cenobamate | 12 | suppressed |
| Epidiolex | Cannabidiol (Cbd) | 11 | suppressed |
| Gocovri | Amantadine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,772.10 · 439 records | LivaNova USA, Inc. | AUSTEDO XR, Briviact, CAPLYTA, CREXONT, FYCOMPA, Fintepla, Gocovri, INGREZZA, KESIMPTA, KISUNLA, LEQEMBI, Motpoly XR, NURTEC ODT, Nayzilam, PONVORY, QULIPTA, REXULTI, Rystiggo, TANLOR, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VNS Therapy, VRAYLAR, VUMERITY, VYEPTI, VYVGART HYTRULO, WaveWriter Alpha Prime 16, XCOPRI, ZAVZPRET, ZTLido | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error